People News: Alexion Pharmaceuticals and KV Pharmaceutical
Specialty firm KV Pharmaceutical named David Van Vliet CEO, with a term through December 31, 2011. Van Vliet has served as interim president and CEO since December 2008.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.